Researchers from the University of Adelaide have embarked on a comprehensive examination of the oral formulations of widely prescribed weight management pharmaceuticals, specifically focusing on the compound salcaprozate sodium (SNAC). This substance is a critical component in enabling the absorption of semaglutide when administered in tablet form, serving as an absorption enhancer. Emerging findings from their recent investigations suggest that SNAC may exert biological effects that extend beyond its primary function of facilitating drug uptake, prompting a deeper scientific inquiry into its role within the human body.
This latest research represents a pioneering in vivo study designed to systematically assess the impact of sustained, repeated exposure to SNAC on the delicate ecosystem of the gut microbiota, overall metabolic function, and associated physiological health indicators. The scientific team conducted a controlled experiment utilizing an animal model over a three-week period, during which they meticulously documented several significant physiological alterations. These observed changes included a notable increase in the abundance of certain bacterial species within the gut, alongside a measurable rise in specific inflammatory markers. Furthermore, the study indicated a decrease in the levels of specific proteins that have been previously linked to cognitive function, raising questions about potential broader implications.
It is crucial to emphasize that the current research does not definitively establish SNAC as a harmful agent. However, the data generated from this study strongly suggest that the absorption-enhancing compound might influence bodily processes in ways that are distinct from its intended purpose of merely enabling the oral bioavailability of semaglutide. This distinction is significant, as it highlights the possibility of unintended biological consequences arising from the presence and activity of SNAC in the gastrointestinal tract.
The strategic inclusion of SNAC in the development of oral semaglutide formulations is directly tied to the challenges of delivering peptide-based drugs like semaglutide effectively when taken by mouth. Semaglutide, the active pharmaceutical ingredient in prominent weight loss medications such as Wegovy and Ozempic, operates differently depending on its administration route. When administered via injection, semaglutide bypasses the digestive system and enters the bloodstream directly, ensuring its full potency. In contrast, when formulated as a tablet, semaglutide faces a hostile environment within the stomach, where it is susceptible to degradation by potent digestive enzymes. SNAC’s role is to act as a protective shield, preventing this breakdown, and simultaneously facilitating the passage of semaglutide across the intestinal wall into the systemic circulation. Without the synergistic action of SNAC, oral semaglutide would largely be ineffective, failing to achieve therapeutically relevant concentrations in the bloodstream.
The landscape of pharmaceutical delivery for semaglutide has recently evolved with the United States granting approval for a tablet version of Wegovy late last year. This development, coupled with the inherent convenience and potential for reduced cost often associated with oral medications compared to injectable alternatives, portends a significant increase in the daily exposure of individuals to SNAC. As more patients opt for the accessibility of pill-based therapies, the cumulative intake of SNAC across the population is expected to rise substantially.
This surge in oral semaglutide use occurs against a backdrop of a global public health crisis characterized by escalating rates of obesity. Obesity is a multifaceted and chronic condition with profound and far-reaching health consequences, affecting hundreds of millions of people worldwide. Current estimates indicate that approximately 890 million adults and 160 million children globally are living with obesity, a figure that translates to roughly one in every eight individuals on the planet. Within the Organisation for Economic Co-operation and Development (OECD) countries, the United States stands out with the highest prevalence, where 43% of individuals aged 15 and older are affected. Australia ranks sixth among these nations, with 31% of its population experiencing obesity, surpassing the OECD average of 25%.
Reflecting these broader global trends, the prescription rates for advanced weight management medications, including Ozempic and Wegovy, have witnessed a dramatic and accelerated increase in Australia over the past few years. This heightened demand underscores the growing reliance on pharmacological interventions to address the complex challenges of weight management.
The researchers at Adelaide University are advocating for a more thorough and extensive investigation into the long-term implications of SNAC. Lead author Amin Ariaee, a doctoral candidate at the university, underscores the critical importance of fully comprehending the impact of every constituent ingredient within these rapidly expanding oral obesity treatments. He highlights that as oral semaglutide therapies become more prevalent, a comprehensive understanding of how repeated and prolonged exposure to all components, not just the active drug, affects the human body is imperative.
Ariaee acknowledges the significant therapeutic benefits of these medications, stating, "Obesity is a complex, chronic disease with serious health consequences. These medicines are highly effective and are helping many people." However, he reiterates the need for continued vigilance and scientific scrutiny. "But as oral versions become more widely used, we need to understand what repeated, long-term exposure to all ingredients in the pill means for the body — not just the active drug." He elaborates on the study’s findings, noting, "While SNAC enables semaglutide to be taken as a tablet, our study found that it was also associated with shifts in potentially harmful gut bacteria, elevated inflammatory markers and depletion of proteins linked to cognitive impairment. These findings warrant further investigation."
Senior Research Fellow Dr. Paul Joyce, who was also involved in the study, stresses the preliminary nature of these findings, emphasizing that they originate from animal research and must be interpreted with a degree of caution. He clarifies, "Importantly, our findings do not prove that SNAC causes harm in humans." Nevertheless, he underscores the significance of the observed biological activity, stating, "However, they do show that the ingredient enabling these tablets to work may have adverse biological effects beyond drug absorption." Dr. Joyce concludes by reinforcing the necessity of a holistic approach to evaluating these therapeutic agents, particularly given their widespread and often prolonged use. "These medicines are typically taken daily and often for long periods. As their use expands globally, it becomes increasingly important to evaluate all components of these therapies, not just the active compound." This call for further research aims to ensure the long-term safety and efficacy of oral semaglutide formulations by thoroughly investigating the multifaceted role of SNAC within the human physiological system.
About the Author
